Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ASGR1 | P07306 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20439229 | 0.86 | SMN1; SMN2 (0.35) | TSHRASGR1SMN1; SMN2 | |
| SCHEMBL14822523 | 0.85 | TSHR (0.41) | TSHRSMN1; SMN2PRKCAMEN1THRB | |
| SCHEMBL11414909 | 0.84 | TSHR (0.42) | TSHRASGR1SMN1; SMN2PRKCAMEN1 | |
| SCHEMBL9218290 | 0.82 | EPHX1 (0.35) | EPHX1 | |
| SCHEMBL15129822 | 0.78 | HTT (0.44) | TSHRASGR1PRKCAMEN1THRB | |
| SCHEMBL8308487 | 0.78 | HTT (0.44) | TSHRASGR1PRKCAMEN1THRB | |
| SCHEMBL9619348 | 0.77 | EPHX1 (0.37) | PRKCAEPHX1 | |
| SCHEMBL11327246 | 0.76 | SMN1; SMN2 (0.41) | TSHRASGR1SMN1; SMN2MEN1THRB | |
| SCHEMBL16298823 | 0.76 | ASGR1 (0.31) | ASGR1 | |
| SCHEMBL21235521 | 0.75 | EPHX1 (0.32) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097593-B1 | Lipid A and other carbohydrate ligand analogs | ONCOTHYREON INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20120003295-A1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | ONCOTHYREON INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7820627-B2 | Lipid A and other carbohydrate ligand analogs | ONCOTHYREON INC. (US) | 2010-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003295-A1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | SELPLG, STT3A, LY96 | TSHR 628/4885ASGR1 15/4885SMN1; SMN2 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.